Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.25), $0.07 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $175.4 million versus the consensus estimate of $172.35 million.

GUIDANCE:

Intra-Cellular Therapies sees Q4 2024 revenue of $665-685 million, versus the consensus of $666.6 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.